All Posts
Study commentary: a history of hypothermia for cardiac arrest, 2002-2021 (RIP).
18 Jun, 2021 | 08:20h | UTCA history of hypothermia for cardiac arrest, 2002-2021 (RIP) – PulmCrit
Original study: RCT: In patients with coma after out-of-hospital cardiac arrest, targeted hypothermia did not improve outcomes.
Commentary on Twitter
A history of hypothermia for cardiac arrest, 2002-2021 (RIP)🪦
🥶2002 studies supporting hypothermia were weak
🥶robust studies refute benefit (TTM1 & TTM2)
🥶growing evidence of iatrogenic harm
🥶post-arrest hypothermia should be restricted to within RCTshttps://t.co/GZbpgHXWoD pic.twitter.com/ILUAiqqLQl— 𝙟𝙤𝙨𝙝 𝙛𝙖𝙧𝙠𝙖𝙨 💊 (@PulmCrit) June 17, 2021
RCT: Effects of intravenous Eptinezumab vs. placebo on headache pain and most bothersome symptom when initiated during a migraine attack.
18 Jun, 2021 | 08:16h | UTCEffects of Intraven.ous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Acute Treatment for Migraine: Contemporary Treatments and Future Directions (free for a limited period)
Commentary: Migraine Prevention Drug Eptinezumab Shows Efficacy in Treating Acute Attacks – Physician’s Weekly
Commentary on Twitter (thread – click for more)
Science marches breathlessly forward – or, at least tries to expand its indication.
Anti–calcitonin gene-related peptide antibody infusion, again, vs. placebo.
— Ryan Radecki, MD MS (@emlitofnote) June 17, 2021
[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.
17 Jun, 2021 | 09:55h | UTCOriginal study (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv
Commentaries: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients – Science AND Antibody combo cuts COVID deaths by 20% in very ill seronegative patients – CIDRAP AND Regeneron antibody saves lives in some hospitalized Covid patients, study finds – STAT AND Expert reaction to press release from the RECOVERY trial reporting that Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response – Science Media Centre
Commentary on Twitter
RECOVERY Pre-print:
In patients hospitalised with COVID-19 but no natural antibody response, monoclonal antibody infusion:
– reduced mortality
– increased speed of discharge
– reduced progression to invasive mechanical ventilation or deathhttps://t.co/rpDk4eUhmm pic.twitter.com/wXegKcDZg8— Martin Landray (@MartinLandray) June 16, 2021
M-A: Acute treatments for episodic migraine in adults.
18 Jun, 2021 | 08:18h | UTCAcute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis – JAMA (free for a limited period)
Editorial: Acute Treatment for Migraine: Contemporary Treatments and Future Directions (free for a limited period)
Commentary on Twitter (thread – click for more)
Science marches breathlessly forward – or, at least tries to expand its indication.
Anti–calcitonin gene-related peptide antibody infusion, again, vs. placebo.
— Ryan Radecki, MD MS (@emlitofnote) June 17, 2021
RCT: Tofacitinib reduced the risk of death or respiratory failure in patients hospitalized with Covid-19 pneumonia.
17 Jun, 2021 | 09:58h | UTCTofacitinib in Patients Hospitalized with Covid-19 Pneumonia – New England Journal of Medicine
Commentary on Twitter:
Patients who were hospitalized with #COVID19 pneumonia were randomly assigned, at a median of 10 days after symptom onset, to receive tofacitinib or placebo. At 28 days, the risk of death or respiratory failure was lower in the tofacitinib group. #IDTwitter
— NEJM (@NEJM) June 16, 2021
Differential diagnosis of uncommon prostate diseases: combining mpMRI and clinical information.
18 Jun, 2021 | 08:13h | UTC
Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination.
17 Jun, 2021 | 09:43h | UTCCommentary: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology
Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
CDC now calls coronavirus Delta variant a ‘variant of concern’.
17 Jun, 2021 | 09:53h | UTCCDC now calls coronavirus Delta variant a ‘variant of concern’ – CNN
Guidance: SARS-CoV-2 Variant Classifications and Definitions – Centers for Disease Control and Prevention
Commentary on Twitter
BREAKING—CDC now officially declares #DeltaVariant a “variant of concern”—because much more transmissible (50% faster than #B117, 2x than original strain), more severe (2.5x hospitalization risk than B117, 4x original) & 1 dose vaccine evasive.🧵 #COVID19https://t.co/jZCgfzFLla pic.twitter.com/SszvXuysze
— Eric Feigl-Ding (@DrEricDing) June 15, 2021
[Press release – not published yet] CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy.
17 Jun, 2021 | 09:49h | UTCCureVac Fails in Pivotal COVID-19 Vaccine Trial With 47% Efficacy – AP / Reuters
Press release: CureVac provides update on phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV
Commentary on Twitter (thread – click for more)
https://twitter.com/hildabast/status/1405276204526039041
Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination.
17 Jun, 2021 | 09:45h | UTCMyocarditis after BNT162b2 and mRNA-1273 Vaccination – Circulation
Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
RCT: In patients with coma after out-of-hospital cardiac arrest, targeted hypothermia did not improve outcomes.
17 Jun, 2021 | 09:39h | UTCNews release: Induced hypothermia after cardiac arrest did not improve survival – Lund University
Infographic: The TTM2 Trial – CanadianEM
Commentary: Hypothermia or Normothermia after Cardiac Arrest – NEJM Resident 360
Video: TTM2 Results Presentation Livestream – Critical Care Reviews
Commentary on Twitter (thread – click for more)
The #TTM2trial was published today in the @NEJM https://t.co/jccLB1MO64
Here’s a summary of what we did, what I think the trial means, and what next.@ttm2trial @nielsen_niklas @CritCareReviews @NEJM— Paul Young (@DogICUma) June 16, 2021
Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination.
17 Jun, 2021 | 09:41h | UTCRelated: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Systematic review: Safety and effectiveness of metformin in patients with reduced renal function – safe and beneficial at a eGFR of 45 mL/min/1.73m2 or higher; possibly harmful at an eGFR of less than 30 mL/min/1.73m2.
17 Jun, 2021 | 09:37h | UTC
Commentary on Twitter
Safety of metformin for T2 diabetes in people with reduced kidney function
Associated with ⬇️ mortality and no ⬆️ risk of acidosis at an eGFR of > 45
Associated with fewer benefits & possible ⬆️ in the risk of acidosis at an eGFR <30 https://t.co/uOyarn11hM@goKDIGO pic.twitter.com/Ca05gc7FHi
— Prof Kamlesh Khunti (@kamleshkhunti) June 16, 2021
Review: chronic pelvic pain in women.
17 Jun, 2021 | 09:36h | UTCChronic Pelvic Pain in Women: A Review – JAMA (free for a limited period)
Audio clinical review: Diagnosis and Clinical Care of Women With Chronic Pelvic Pain
Almost 25% of COVID-19 patients develop long-lasting symptoms, according to a new report.
16 Jun, 2021 | 08:31h | UTCAlmost 25% of COVID-19 Patients Develop Long-Lasting Symptoms, According to a New Report – TIME
Original report: A Detailed Study of Patients with Long-Haul COVID – FAIR Health
Commentary on Twitter (thread – click for more)
📍1 in 4–almost a quarter of people infected develop at least one lingering health problem after 30 days with #COVID19. The most common included pain, breathing trouble, high cholesterol, malaise and/or fatigue and high blood pressure. 🧵 https://t.co/G4uPtnq86A
— Eric Feigl-Ding (@DrEricDing) June 15, 2021
Cardio-pulmonary sequelae in recovered COVID-19 patients: considerations for primary care.
16 Jun, 2021 | 08:29h | UTC
The authorship rows that sour scientific collaborations.
17 Jun, 2021 | 09:34h | UTCThe authorship rows that sour scientific collaborations – Nature
M-A: The incubation period distribution of coronavirus disease 2019 – “the mean incubation period of COVID-19 was likely to fall between 5.2 and 7.2 days, and the 95th percentile would be between 11 and 14.6 days”.
16 Jun, 2021 | 08:27h | UTC
A long-term perspective on immunity to COVID – “Clinical studies now indicate that immunity will be long-lasting”.
16 Jun, 2021 | 08:26h | UTCA long-term perspective on immunity to COVID – Nature
Review: venous and arterial thromboembolism in patients with cancer.
16 Jun, 2021 | 08:20h | UTCSummary: Venous and Arterial Thromboembolism in Patients With Cancer – American College of Cardiology
France recommends single dose of vaccine if previous Covid infection detected.
16 Jun, 2021 | 08:24h | UTCFrance recommends single dose of vaccine if previous Covid infection detected – Rfi
Related: [Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19. AND Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19
M-A: Extracorporeal membrane oxygenation for COVID-19.
16 Jun, 2021 | 08:22h | UTC
AHA Scientific Statement: Mechanical Complications of Acute Myocardial Infarction.
16 Jun, 2021 | 08:21h | UTC
Randomized, sham-controlled pilot study: percutaneous peripheral nerve stimulation (neuromodulation) for postoperative pain.
16 Jun, 2021 | 08:17h | UTCCommentary: Peripheral Nerve Stimulation May Cut Pain After Orthopedic Surgery – HealthDay
The BMJ Series: The future of nursing.
16 Jun, 2021 | 08:18h | UTCHomepage: The future of nursing – The BMJ
How to reposition the nursing profession for a post-covid age
How the nursing profession should adapt for a digital future
How to attain gender equality in nursing—an essay
Nursing’s pivotal role in global climate action